Lantus SoloStar

Lantus is a widely prescribed long-acting insulin used for the treatment of diabetes. It was developed by the pharmaceutical division of Sanofi, a French multinational healthcare company. The SoloStar variant refers to the pre-filled disposable pen delivery system used for its administration.

Sanofi maintains extensive manufacturing networks across Europe and North America. The insulin glargine itself is primarily produced in high-tech facilities in Frankfurt, Germany, which is one of the world's largest sites for insulin production. The assembly of the SoloStar pen devices and final packaging often occurs in France, though secondary manufacturing sites exist in other regions to meet global demand. Sanofi remains the ultimate owner and distributor of Lantus, maintaining its headquarters in Paris, France.